Ketamine Therapy Blog — Mental Health Insights & Treatment Guides
Expert insights on ketamine therapy, depression, anxiety, PTSD, and mental health treatment — updated regularly by the Isha Health clinical team.
The Montreal Model: Ketamine Therapy for Alcohol + Depression
A 2026 feasibility trial protocol combines structured ketamine therapy with psychotherapy for alcohol use disorder and treatment-resistant depression.
Group Ketamine Therapy for Identity-Based Trauma
A 2026 pilot study tested group ketamine-assisted psychotherapy for transgender adults experiencing identity-based trauma. Results showed significant improvements.
Trauma-Informed Care During Ketamine Treatment
Patients referred for ketamine therapy often have complex trauma histories. A 2026 clinical protocol outlines trauma-informed nursing practices for safe, effective treatment.
Ketamine and Your Gut: The Microbiome Connection
New research reveals a bidirectional relationship between ketamine and the gut microbiome. How gut bacteria may influence ketamine's antidepressant effects.
Ketamine for Depression in Older Adults with MCI
Can ketamine treat depression in older adults with mild cognitive impairment? A 2026 editorial in the American Journal of Geriatric Psychiatry examines the evidence.
Ketamine + Mindfulness for Opioid Addiction: RCT Results
A 2026 Nature Mental Health RCT found ketamine-assisted mindfulness therapy significantly reduced drug use and cravings in patients with opioid use disorder.
Psychedelic Medicine in 2026: Where We Stand
From ketamine clinics to psilocybin trials and MDMA setbacks — a physician's overview of where psychedelic medicine stands in 2026 and what's next.
6 Weeks of Oral Ketamine for TRD, PTSD, and OCD
A 2025 open-label study tested six weeks of oral ketamine for treatment-resistant depression, PTSD, and OCD. Improvements sustained across all three conditions.
Why Some Patients Respond Better to Ketamine
A pharmacogenetics pilot study explores why some patients respond better to esketamine. Genetic, clinical, and demographic variables all play a role.
Oral Ketamine for Depression: New RCT + Meta-Analysis
A 2025 randomized controlled trial and meta-analysis found oral ketamine effective for major depressive and bipolar disorder, with an NNT of 4.6.
Psychedelics for Borderline Personality Disorder?
A 2026 narrative review examines ketamine, esketamine, and psilocybin for BPD. Preliminary evidence suggests they may be safe and potentially beneficial.
Extended-Release Ketamine Tablets: Phase 2 Trial Results
A Nature Medicine Phase 2 RCT tested extended-release oral ketamine tablets for treatment-resistant depression. Results show efficacy with minimal side effects.
Page 1 of 17
Get new articles in your inbox
Research updates and clinical insights on ketamine therapy — no spam.